TRANSGENIC ANIMAL MODEL OF MOOD DISORDERS

(19)

(11)

EP 2 827 706 B8

(12)	CORRECTED EUROPEAN PATENT SPECIFICATION
	Note: Bibliography reflects the latest situation

(15)	Correction information:
	Corrected version no 1 (W1 B1)

(48)	Corrigendum issued on:
	02.08.2017 Bulletin 2017/31

(45)	Mention of the grant of the patent:
	12.04.2017 Bulletin 2017/15

(21)	Application number: 13711608.3

(22)	Date of filing: 14.03.2013

(51)

International Patent Classification (IPC):

A01K 67/027^(2006.01)
G01N 33/68^(2006.01)
C07K 16/22^(2006.01)
C12N 15/113^(2010.01)

C07K 14/475^(2006.01)
C12N 15/85^(2006.01)
C12Q 1/68^(2006.01)
G01N 33/50^(2006.01)

(86)	International application number:
	PCT/EP2013/055253

(87)	International publication number:
	WO 2013/139676 (26.09.2013 Gazette 2013/39)

(54)	TRANSGENIC ANIMAL MODEL OF MOOD DISORDERS TRANSGENES TIERMODELL FÜR GEMÜTSKRANKHEITEN MODÈLE D'ANIMAL TRANSGÉNIQUE POUR LES TROUBLES DE L'HUMEUR

(84)	Designated Contracting States:
	AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30)

Priority:

19.03.2012 GB 201204816

(43)	Date of publication of application:
	28.01.2015 Bulletin 2015/05

(73)	Proprietors:
	Progenika Biopharma, S.A. 48160 Derio (Bizkaia) (ES) Universidad del País Vasco/Euskal Herriko Unibertsitatea 48940 Leoia, Bikaia (ES)

(72)	Inventors:
	ARTETA, David 48160 Derio (ES) FERRER, Marcelo 48160 Derio (ES) SIMÓN, Laureano 48160 Derio (ES) MARTINEZ, Antonio 48160 Derio (ES) URIBARRI, Maria 48160 Derio (ES) MEANA, José Javier 48940, Leoia, Bikaia (ES) CALLADO, Luis Felipe 48940, Leoia, Bikaia (ES)

(74)	Representative: Casley, Christopher Stuart et al
	Mewburn Ellis LLP City Tower 40 Basinghall Street London EC2V 5DE London EC2V 5DE (GB)

(56)

References cited: :

WO-A1-01/64944
WO-A1-2011/154037
WO-A2-2004/047727
WO-A2-2005/047530
WO-A2-2006/020684

WO-A1-2010/039526
WO-A2-01/84921
WO-A2-2005/017203
WO-A2-2006/002262

I PAVLOV: "Role of Heparin-Binding Growth-Associated Molecule (HB-GAM) in Hippocampal LTP and Spatial Learning Revealed by Studies on Overexpressing and Knockout Mice", MOLECULAR AND CELLULAR NEUROSCIENCE, vol. 20, no. 2, June 2002 (2002-06), pages 330-342, XP055062718, ISSN: 1044-7431, DOI: 10.1006/mcne.2002.1104 cited in the application
MIGUEL A GAMA SOSA ET AL: "Modeling human neurodegenerative diseases in transgenic systems", HUMAN GENETICS, SPRINGER, BERLIN, DE, vol. 131, no. 4, 14 December 2011 (2011-12-14), pages 535-563, XP035029261, ISSN: 1432-1203, DOI: 10.1007/S00439-011-1119-1
N TAKAHASHI ET AL: "Increased expression of receptor phosphotyrosine phosphatase-[beta]/[zeta] is associated with molecular, cellular, behavioral and cognitive schizophrenia phenotypes", TRANSLATIONAL PSYCHIATRY, vol. 1, no. 5, May 2011 (2011-05), page e8, XP055062757, DOI: 10.1038/tp.2011.8
ANONYMOUS: 'Tissue expression of PTN - Summary - The Human Protein Atlas' INTERNET ARTICLE, [Online] 01 January 2016, XP055245302 Retrieved from the Internet: <URL:http://www.proteinatlas.org/ENSG000001 05894-PTN/tissue> [retrieved on 2016-01-27]

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).